Get startedLog in
    Picture of Theriva Biologics logo

    TOVX — Theriva Biologics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapSucker Stock
    All News

    Brief: Theriva Biologics Announces Dosing Of First Patient In The Investigator Sponsored Phase 1 Trial Of Vcn-01, An Intravenous Oncolytic Adenovirus, In Patients With Brain Tumors

    Picture of Theriva Biologics logoTheriva Biologics
    09/01/2023 13:28
    Jan 9 (Reuters) - Theriva Biologics Inc  TOVX.A :
    * THERIVA BIOLOGICS ANNOUNCES DOSING OF FIRST PATIENT IN THE
INVESTIGATOR SPONSORED PHASE 1 TRIAL OF VCN-01, AN INTRAVENOUS
ONCOLYTIC ADENOVIRUS, IN PATIENTS WITH BRAIN TUMORS

Source text for Eikon:  ID:nGNXc4rnBB 
Further company coverage:  TOVX.A 
 ((reuters.briefs@thomsonreuters.com;))

    Recent news on Theriva Biologics

    See all news